Literature DB >> 6783055

Plasma diazepam and desmethyldiazepam concentrations during long-term diazepam therapy.

D J Greenblatt, T P Laughren, M D Allen, J S Harmatz, R I Shader.   

Abstract

1 Factors influencing steady-state plasma concentrations of diazepam (DZ) and its major metabolite desmethyldiazepam (DMDZ) were assessed in 110 male Veterans Administration outpatient clinic patients (mean age 53 years). 2 Patients reportedly had taken DZ for 1 to 14 years (mean duration 5.1 years) at a mean daily dose of 20 mg (range 2 to 55 mg). 3 Steady-state plasma concentrations of DZ (mean 329 ng/ml) and DMDZ (mean 389 ng/ml) were highly correlated (r = 0.80), with a mean DMDZ/DZ ratio of 1.26. 4 Weight-corrected daily dose were significantly correlated with plasma level of DZ (r = 0.32), DMDZ (r = 0.38) and the sum of DZ plus DMDZ (r = 0.37), but explained a small fraction of individual variation. 5 Duration of therapy, smoking habits, alcohol consumption, and number of other drugs coingested were not significantly related to plasma level.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6783055      PMCID: PMC1401701          DOI: 10.1111/j.1365-2125.1981.tb01099.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Pharmacokinetic understanding of antianxiety drug therapy.

Authors:  D J Greenblatt; R I Shader
Journal:  South Med J       Date:  1978-08       Impact factor: 0.954

2.  Pharmacokinetics of diazepam following multiple-dose oral administration to healthy human subjects.

Authors:  F B Eatman; W A Colburn; H G Boxenbaum; H N Posmanter; R E Weinfeld; R Ronfeld; L Weissman; J D Moore; M Gibaldi; S A Kaplan
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Plasma concentrations of diazepam and desmethyldiazepam during chronic diazepam therapy.

Authors:  D M Rutherford; A Okoko; P J Tyrer
Journal:  Br J Clin Pharmacol       Date:  1978-07       Impact factor: 4.335

4.  Simultaneous gas-chromatographic analysis for diazepam and its major metabolite, desmethyldiazepam, with use of double internal standardization.

Authors:  D J Greenblatt
Journal:  Clin Chem       Date:  1978-10       Impact factor: 8.327

5.  Plasma concentrations of benzodiazepines.

Authors:  A J Bond; D M Hailey; M H Lader
Journal:  Br J Clin Pharmacol       Date:  1977-02       Impact factor: 4.335

6.  Comparison of the pharmacokinetics of diazepam after single and subchronic doses.

Authors:  U Klotz; K H Antonin; P R Bieck
Journal:  Eur J Clin Pharmacol       Date:  1976-06-15       Impact factor: 2.953

7.  Inter- and intrasubject variation in diazepam free fraction.

Authors:  J G Abel; E M Sellers; C A Naranjo; J Shaw; D Kadar; M K Romach
Journal:  Clin Pharmacol Ther       Date:  1979-08       Impact factor: 6.875

8.  Factors influencing blood concentrations of chlordiazepoxide: a use of multiple regression analysis.

Authors:  D J Greenblatt; J S Harmatz; D R Stanski; R I Shader; K Franke; J Koch-Weser
Journal:  Psychopharmacology (Berl)       Date:  1977-11-15       Impact factor: 4.530

9.  Diazepam disposition determinants.

Authors:  D J Greenblatt; M D Allen; J S Harmatz; R I Shader
Journal:  Clin Pharmacol Ther       Date:  1980-03       Impact factor: 6.875

10.  Correlates of outcome following acute glutethimide overdosage.

Authors:  D J Greenblatt; M D Allen; J S Harmatz; B J Noel; R I Shader
Journal:  J Forensic Sci       Date:  1979-01       Impact factor: 1.832

View more
  11 in total

Review 1.  Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II).

Authors:  D J Greenblatt; J S Harmatz; R I Shader
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

2.  Clearance of diazepam can be impaired by its major metabolite desmethyldiazepam.

Authors:  U Klotz; I Reimann
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

3.  Inhibition of recombinant L-type voltage-gated calcium channels by positive allosteric modulators of GABAA receptors.

Authors:  Damien E Earl; Elizabeth I Tietz
Journal:  J Pharmacol Exp Ther       Date:  2011-01-24       Impact factor: 4.030

4.  Diazepam increases the hypothalamic-pituitary-adrenocortical (HPA) axis activity by a cyclic AMP-dependent mechanism.

Authors:  M L Vargas; C Abella; J Hernandez
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

Review 5.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

6.  Flumazenil-precipitated withdrawal in healthy volunteers following repeated diazepam exposure.

Authors:  Miriam Z Mintzer; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2004-09-25       Impact factor: 4.530

7.  Determinants of benzodiazepine brain uptake: lipophilicity versus binding affinity.

Authors:  R M Arendt; D J Greenblatt; D C Liebisch; M D Luu; S M Paul
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

8.  Actual versus reported benzodiazepine usage by medical outpatients.

Authors:  H R Ochs; L G Miller; D J Greenblatt; R I Shader
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 9.  Benzodiazepine dependence. A review of the evidence.

Authors:  R T Owen; P Tyrer
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

10.  Binding of diazepam and desmethyldiazepam to plasma protein: concentration-dependence and interactions.

Authors:  M Divoll; D J Greenblatt
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.